Your browser doesn't support javascript.
loading
Health-related quality-of-life impact of pembrolizumab versus best supportive care in previously systemically treated patients with advanced hepatocellular carcinoma: KEYNOTE-240.
Ryoo, Baek-Yeol; Merle, Philippe; Kulkarni, Amit S; Cheng, Ann-Lii; Bouattour, Mohamed; Lim, Ho Yeong; Breder, Valeriy; Edeline, Julien; Chao, Yee; Ogasawara, Sadahisa; Yau, Thomas; Garrido, Marcelo; Chan, Stephen L; Daniele, Bruno; Norquist, Josephine M; Chen, Erluo; Siegel, Abby B; Zhu, Andrew X; Finn, Richard S; Kudo, Masatoshi.
Afiliação
  • Ryoo BY; Asan Medical Center, University of Ulsan College of Medicine, Seoul, South Korea.
  • Merle P; Croix-Rousse Hospital, Hospices Civils de Lyon, Lyon, France.
  • Kulkarni AS; Merck & Co., Inc., Kenilworth, New Jersey.
  • Cheng AL; National Taiwan University Cancer Center, Taipei City, Taiwan.
  • Bouattour M; Beaujon Hospital, Assistance Publique-Hôpitaux de Paris, Clichy, France.
  • Lim HY; Samsung Medical Center, Sungkyunkwan University, Seoul, South Korea.
  • Breder V; N. N. Blokhin National Medical Research Center of Oncology, Moscow, Russia.
  • Edeline J; Centre Eugene Marquis, Rennes, France.
  • Chao Y; Taipei Veterans General Hospital, Taipei City, Taiwan.
  • Ogasawara S; Department of Gastroenterology, Graduate School of Medicine, Chiba University, Chiba, Japan.
  • Yau T; The University at Hong Kong, Hong Kong, People's Republic of China.
  • Garrido M; Pontifical Catholic University of Chile, Santiago, Chile.
  • Chan SL; State Key Laboratory of Translational Oncology, Department of Clinical Oncology, The Chinese University of Hong Kong, Sha Tin, Hong Kong.
  • Daniele B; Hospital of the Sea, Napoli, Italy.
  • Norquist JM; Merck & Co., Inc., Kenilworth, New Jersey.
  • Chen E; Merck & Co., Inc., Kenilworth, New Jersey.
  • Siegel AB; Merck & Co., Inc., Kenilworth, New Jersey.
  • Zhu AX; Massachusetts General Hospital Cancer Center and Harvard Medical School, Boston, Massachusetts.
  • Finn RS; Jiahui International Cancer Center, Jiahui Health, Shanghai, China.
  • Kudo M; David Geffen School of Medicine at University of California Los Angeles, Los Angeles, California.
Cancer ; 127(6): 865-874, 2021 03 15.
Article em En | MEDLINE | ID: mdl-33231873
Assuntos
Palavras-chave
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Qualidade de Vida / Carcinoma Hepatocelular / Anticorpos Monoclonais Humanizados / Neoplasias Hepáticas Tipo de estudo: Clinical_trials / Prognostic_studies Limite: Humans Idioma: En Revista: Cancer Ano de publicação: 2021 Tipo de documento: Article País de afiliação: Coréia do Sul
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Qualidade de Vida / Carcinoma Hepatocelular / Anticorpos Monoclonais Humanizados / Neoplasias Hepáticas Tipo de estudo: Clinical_trials / Prognostic_studies Limite: Humans Idioma: En Revista: Cancer Ano de publicação: 2021 Tipo de documento: Article País de afiliação: Coréia do Sul